NO20043591L - Makrosykliske peptider aktive mot hepatitt C virus - Google Patents

Makrosykliske peptider aktive mot hepatitt C virus

Info

Publication number
NO20043591L
NO20043591L NO20043591A NO20043591A NO20043591L NO 20043591 L NO20043591 L NO 20043591L NO 20043591 A NO20043591 A NO 20043591A NO 20043591 A NO20043591 A NO 20043591A NO 20043591 L NO20043591 L NO 20043591L
Authority
NO
Norway
Prior art keywords
alkyl
virus
active against
against hepatitis
macrocyclic peptides
Prior art date
Application number
NO20043591A
Other languages
English (en)
Inventor
Montse Llinas-Brunet
Vida J Gorys
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Publication of NO20043591L publication Critical patent/NO20043591L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Forbindelser med formel. (1), eller et farmasøytisk. akseptabelt salt derav,. nyttige som inhibitorer av. HCV NS3-proteasen.Forbindelser med formel (I),. hvor Rer hydroksy eller NHS0R, hvor Rer (C-)alkyl, (C^cykloalkyl eller {(C.g)alkyl(C-)cykloalkyl}, som alle eventuelt er substituert fra 1 til 3 ganger med halogen, cyano, nitro, 0(C)alkyl, amido, amino eller fenyl, eller Rer Ce- eller C-aryl som eventuelt er substituert fra 1 til 3 ganger med halogen, cyano, nitro, (C)alkyl, 0(C,.)alkyl, amido, amino eller fenyl; R2 er (C)cykloalkyl og Rer cyklopentyl, eller et farmasøytisk akseptabelt saft derav, nyttige som inhibitorer av HCV NS3-proteasen.
NO20043591A 2002-01-30 2004-08-27 Makrosykliske peptider aktive mot hepatitt C virus NO20043591L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002369711A CA2369711A1 (en) 2002-01-30 2002-01-30 Macrocyclic peptides active against the hepatitis c virus
PCT/CA2003/000089 WO2003064455A2 (en) 2002-01-30 2003-01-24 Macrocyclic peptides active against the hepatitis c virus

Publications (1)

Publication Number Publication Date
NO20043591L true NO20043591L (no) 2004-08-27

Family

ID=27626541

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043591A NO20043591L (no) 2002-01-30 2004-08-27 Makrosykliske peptider aktive mot hepatitt C virus

Country Status (26)

Country Link
US (1) US20030181363A1 (no)
EP (1) EP1472278B1 (no)
JP (1) JP4040578B2 (no)
KR (1) KR20040077899A (no)
CN (1) CN1639187A (no)
AR (1) AR038330A1 (no)
AT (1) ATE414098T1 (no)
BR (1) BR0307297A (no)
CA (1) CA2369711A1 (no)
DE (1) DE60324660D1 (no)
EA (1) EA007738B1 (no)
EC (1) ECSP045243A (no)
ES (1) ES2316718T3 (no)
HR (1) HRP20040689A2 (no)
MX (1) MXPA04007462A (no)
NO (1) NO20043591L (no)
NZ (1) NZ534929A (no)
PE (1) PE20030818A1 (no)
PL (1) PL371007A1 (no)
RS (1) RS67004A (no)
SA (1) SA03230569B1 (no)
TW (1) TW200307692A (no)
UA (1) UA78014C2 (no)
UY (1) UY27630A1 (no)
WO (1) WO2003064455A2 (no)
ZA (1) ZA200405639B (no)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1337550B1 (en) 2000-11-20 2006-05-24 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
AU2003248535A1 (en) 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60336550D1 (de) 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
WO2004043339A2 (en) 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) * 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
BRPI0410456B8 (pt) 2003-05-21 2021-05-25 Boehringer Ingelheim Int compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
ATE457995T1 (de) 2003-06-18 2010-03-15 Tranzyme Pharma Inc Makrozyklische motilin rezeptorantagonisten
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
ATE500264T1 (de) * 2003-09-22 2011-03-15 Boehringer Ingelheim Int Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus
WO2005037214A2 (en) * 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2539575C (en) * 2003-11-20 2015-01-20 Boehringer Ingelheim International Gmbh Method of removing transition metals, especially from metathesis reaction products
ATE424926T1 (de) * 2003-12-08 2009-03-15 Boehringer Ingelheim Int Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten
JP4682155B2 (ja) * 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
US7671032B2 (en) 2004-01-30 2010-03-02 Medivir Ab HCV NS-3 serine protease inhibitors
EA013207B1 (ru) 2004-02-20 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
JP4950026B2 (ja) * 2004-03-30 2012-06-13 インターミューン・インコーポレーテッド ウイルス複製阻害剤としての大環状化合物
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
PL382845A1 (pl) 2004-07-16 2008-01-21 Gilead Sciences, Inc. Związki przeciwwirusowe
ES2366478T3 (es) 2004-07-20 2011-10-20 Boehringer Ingelheim International Gmbh Análogos peptídicos inhibidores de la hepatitis c.
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP2008513454A (ja) * 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法
EP1794179A1 (en) * 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
CN102160891A (zh) * 2004-10-01 2011-08-24 威特克斯医药股份有限公司 Hcv ns3-ns4a蛋白酶抑制
CA2583152A1 (en) * 2004-10-21 2006-04-27 Pfizer Inc. Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
TW201424733A (zh) 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
DE102005002336A1 (de) * 2005-01-17 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Durchführung von kontinuierlichen Olefin-Ringschluss-Metathesen in komprimiertem Kohlendioxid
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP4705164B2 (ja) * 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR057456A1 (es) * 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
MX2008001166A (es) 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
MX2008001588A (es) * 2005-08-01 2008-02-19 Merck & Co Inc Inhibidores de proteasa ns3 del vhc.
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
KR20080112303A (ko) 2006-03-16 2008-12-24 버텍스 파마슈티칼스 인코포레이티드 중수소화 ｃ형 간염 프로테아제 억제제
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
US8377873B2 (en) 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8309540B2 (en) * 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CA2667031C (en) 2006-10-27 2013-01-22 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010513450A (ja) 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
KR20090111326A (ko) * 2007-02-08 2009-10-26 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 억제 마크로사이클릭 페닐카바메이트
ATE542815T1 (de) 2007-02-27 2012-02-15 Vertex Pharma Kokristalle und pharmazeutische zusammensetzungen damit
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
WO2008141227A1 (en) * 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
AR067180A1 (es) * 2007-06-29 2009-09-30 Gilead Sciences Inc Compuestos antivirales
MX2009013830A (es) 2007-06-29 2010-03-01 Gilead Sciences Inc Compuestos antivirales.
CN101754970B (zh) 2007-07-17 2013-07-10 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎的大环吲哚衍生物
CA2699891C (en) 2007-07-19 2013-10-22 Nigel Liverton Macrocyclic compounds as antiviral agents
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
CN101835774B (zh) 2007-08-30 2014-09-17 弗特克斯药品有限公司 共晶体和包含该共晶体的药物组合物
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
EP2224942A4 (en) 2007-12-05 2012-01-25 Enanta Pharm Inc FLUORATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
AU2009210789B2 (en) 2008-02-04 2014-01-30 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
SG175692A1 (en) 2008-04-15 2011-11-28 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2271345B1 (en) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2540350E (pt) 2008-07-22 2014-08-27 Merck Sharp & Dohme Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ592110A (en) * 2008-11-20 2012-06-29 Achillion Pharmaceuticals Inc Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR074670A1 (es) * 2008-12-19 2011-02-02 Gilead Sciences Inc Inhibidores de la proteasa ns3 del vhc virus de la hepatitis c
CN102271699A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
WO2010093843A2 (en) 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CN102458444A (zh) 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
EP2461811B1 (en) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
BR112012014899A2 (pt) 2009-12-18 2017-03-14 Idenix Pharmaceuticals Inc composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
KR20120139699A (ko) 2010-01-29 2012-12-27 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 감염의 치료 요법
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
US20120014912A1 (en) 2010-07-14 2012-01-19 Vertex Pharmaceuticals Incorporated Palatable pharmaceutical composition
DK2618831T3 (en) 2010-09-21 2016-04-04 Enanta Pharm Inc Macrocyclic prolinafledte HCV serine protease inhibitors
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130195797A1 (en) 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
CN102617705B (zh) * 2012-02-16 2014-12-31 上海纬诺医药科技有限公司 抑制丙肝病毒复制的大环类化合物
CN104822682A (zh) 2012-10-08 2015-08-05 艾伯维公司 用于制备hcv蛋白酶抑制剂的化合物
WO2014062196A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN110256536B (zh) * 2019-05-13 2022-09-13 中国人民解放军第二军医大学 一种抗丙型肝炎病毒感染合成肽及其应用
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus

Also Published As

Publication number Publication date
UY27630A1 (es) 2003-08-29
CA2369711A1 (en) 2003-07-30
EP1472278B1 (en) 2008-11-12
MXPA04007462A (es) 2005-07-13
ECSP045243A (es) 2004-09-28
AR038330A1 (es) 2005-01-12
US20030181363A1 (en) 2003-09-25
CN1639187A (zh) 2005-07-13
UA78014C2 (en) 2007-02-15
EA007738B1 (ru) 2006-12-29
BR0307297A (pt) 2004-12-21
DE60324660D1 (de) 2008-12-24
TW200307692A (en) 2003-12-16
JP4040578B2 (ja) 2008-01-30
KR20040077899A (ko) 2004-09-07
WO2003064455A3 (en) 2004-02-05
SA03230569B1 (ar) 2007-03-05
RS67004A (en) 2006-10-27
EA200400886A1 (ru) 2005-02-24
ES2316718T3 (es) 2009-04-16
NZ534929A (en) 2006-08-31
PL371007A1 (en) 2005-06-13
WO2003064455A2 (en) 2003-08-07
PE20030818A1 (es) 2003-10-30
ZA200405639B (en) 2005-07-01
JP2005524632A (ja) 2005-08-18
EP1472278A2 (en) 2004-11-03
ATE414098T1 (de) 2008-11-15
HRP20040689A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
NO20043591L (no) Makrosykliske peptider aktive mot hepatitt C virus
NO20061767L (no) Makrosykliske peptider som er aktive mot hepatitt C virus
AU2003275826A1 (en) Macrocyclic peptides active against the hepatitis c virus
ATE447573T1 (de) Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2004072243A3 (en) Macrocyclic hepatitis c serine protease inhibitors
NO20060706L (no) Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2002048157A3 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2004014313A3 (en) Combination pharmaceutical agents as inhibitors of hcv replication
NO20044808L (no) Heterosykliske sulfonamider som er hepatitt C virus inhibitorer
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
WO2003087092A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
NO20040127L (no) Brodannede bicykliske serinproteaseinhibitorer
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
NO20052580L (no) Blandinger for behandling av infeksjon av Flavivirida viruser
WO2004101602A3 (en) Hepatitis c inhibitor peptide analogs
NO20081467L (no) Inhibitorer av sennproteaser
NO20053762L (no) Kondensert furanforbindelse.
EP1688420A4 (en) 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
AR046233A1 (es) Derivados de piperidinillactamas, procedimiento para prepararlos y composicion farmaceutica.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application